All News

The holidays are rolling in, which often means reconnecting with friends and family— some of which you haven’t seen in a while.

The recent approval of Fruzaqla (fruquintinib) for patients with pretreated metastatic colorectal cancer (mCRC) offers improved survival with manageable quality of life.

Last week brought three more FDA approvals in the oncology space, as well as some research in neuropathy prevention and the diabetes-cancer connection.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.

While many parts of my cancer experience were extremely difficult, I tried to embrace it — and accept help when needed.

Immune checkpoint inhibitors and stereotactic radiosurgery do not increase the risk of necrosis among patients with NSCLC who have brain metastases, according to research.

If I could go back and talk to my newly diagnosed self, this is what I would say.

Losing someone to cancer never gets easier.

Two research projects have been established to investigate the use of psychical activity to benefit patients with cancer.

I found family in my cancer support groups.

From Dick Vitale to Make-A-Wish’s Miles Scott reveal that they are cancer free, here is what’s happening in the oncology space this week.

The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence.

The Food and Drug Administration accepted a Priority Review for Breyanzi for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments.

The Food and Drug Administration approved Keytruda plus chemotherapy for the treatment of patients with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma.

My visits to the local cancer center were very impactful as a cancer survivor, and I consider that staff a part of my family.

A decade after becoming a bone marrow donor following his brother’s diagnosis of myelofibrosis, former “Queer Eye for the Straight Guy” co-star Thom Filicia is one of the partners behind the Mapping Myelofibrosis initiative.

The Food and Drug Administration approved Augtyro for patients with ROS1-positive metastatic non-small cell lung cancer based on a phase 1/2 trial.

An expert discusses why patients with melanoma may undergo treatment even after their tumor was surgically removed, and how melanoma became the “poster child” for immunotherapy.

Patients with colorectal cancer who had diabetes with complications had an 85% higher risk of death than those without diabetes, according to the findings of a study.

CURE® spoke with the director of oncology pharmacy at Massachusetts General Hospital about recent cancer drug shortages that have been making headlines.

It’s been more than half a year since I rang the bell at the hospital signaling that I was free of non-Hodgkins Lymphoma.

Keytruda plus chemotherapy for patients with locally advanced biliary tract cancer helped increase survival for up to two more years, an expert told CURE®.

Where I grew up, cancer was not openly discussed.

Stereotactic radiation is promising in treating patients with metastatic kidney cancer and may delay the time until patients need further treatment, an expert said.

A multidisciplinary surgical approach decreased death rates by 70% in patients with ovarian cancer.

My diagnosis of prostate cancer gave me an unsuspected gift.